Please check your internet connection and try again.
# Hepamerz (L-Ornithine L-Aspartate / LOLA)
## Overview
L-Ornithine L-Aspartate (LOLA) is a stable salt of two amino acids that serves as a substrate for the urea cycle and glutamine synthesis. It is used to lower blood ammonia levels in patients with liver disease.
## Primary Indications
Treatment of hyperammonemia associated with acute and chronic liver diseases, such as liver cirrhosis and hepatic encephalopathy (HE).
## Adult Dosing
* **Oral (Granules):** 3 g (one sachet) taken 3 times daily after meals. Up to 6 g 3 times daily may be used in severe cases.
* **IV (Infusion):** Up to 20 g (4 ampoules) per 24 hours, administered via IV drip. Dilute ampoules in 500 mL of standard IV fluid (e.g., normal saline or D5W).
* **Rate:** Do not exceed 5 g per hour to avoid nausea.
## Pediatric Dosing
Safety and efficacy in children have not been well established. Dosing is off-label and varies by local institutional protocol; use extreme caution and consult pediatric hepatology guidelines before initiation.
## Dose Adjustments
* **Renal Impairment:** Use with caution in patients with severe renal impairment (serum creatinine >3 mg/dL). Monitoring of blood urea-nitrogen is recommended.
## Contraindications
* Hypersensitivity to the active substance.
* Severe renal insufficiency (renal failure).
## Adverse Effects
* **Gastrointestinal:** Nausea, vomiting, abdominal pain, diarrhea.
* **Systemic:** Transient flushing or itching.
* **Dose-dependent:** High infusion rates significantly increase the incidence of nausea and vomiting.
## Key Drug Interactions
* No major pharmacokinetic drug-drug interactions are documented.
* Caution should be exercised when co-administered with other medications that may exacerbate electrolyte imbalances or renal strain.
## Monitoring
* Monitor serum ammonia levels.
* Monitor BUN and serum creatinine in renally impaired patients.
* Assess clinical status (mental status exam/West Haven criteria) for improvement in hepatic encephalopathy.
## Clinical Pearls
* LOLA acts as a "scavenger" for ammonia by providing substrates for the urea cycle (in hepatocytes) and the glutamine system (in skeletal muscle and periportal hepatocytes).
* Oral granules should be dissolved in liquid (e.g., water, tea, or juice) and consumed immediately after meals.
* There is considerable clinical heterogeneity in response; it should be used as an adjunct to standard-of-care treatments for HE (e.g., lactulose, rifaximin).
* Clinical evidence for long-term efficacy remains debated in some literature; review current institutional guidelines for its place in therapy compared to standard therapies.
***
*Disclaimer: This information is for educational purposes only. Dosing, indications, and clinical guidelines vary by region and institution. Always verify specific dosing, safety warnings, and contraindications via your hospital’s formulary or the official manufacturer’s prescribing information before administration.*
